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Stimulation of the androgen receptor via bioavailable androgens, including testosterone and
testosteronemetabolites, is a key driver of prostate development and the early stages of prostate
cancer. Androgens are hydrophobic and as such require carrier proteins, including sex hormone-
bindingglobulin (SHBG), to enable efficient distribution fromsites of biosynthesis to target tissues.
The similarly hydrophobic corticosteroids also require a carrier protein whose affinity for steroid
is modulated by proteolysis. However, proteolytic mechanisms regulating the SHBG/androgen
complex have not been reported. Here, we show that the cancer-associated serine proteases,
kallikrein-related peptidase (KLK)4 and KLK14, bind strongly to SHBG in glutathione S-transferase
interaction analyses. Further, we demonstrate that active KLK4 and KLK14 cleave human SHBG at
unique sites and in an androgen-dependentmanner. KLK4 separated androgen-free SHBG into its
two laminin G-like (LG) domains that were subsequently proteolytically stable even after pro-
longed digestion, whereas a catalytically equivalent amount of KLK14 reduced SHBG to small
peptide fragments over the sameperiod. Conversely, proteolysis of 5-dihydrotestosterone (DHT)-
bound SHBG was similar for both KLKs and left the steroid binding LG4 domain intact. Charac-
terization of this proteolysis fragment by [3H]-labeledDHTbinding assays revealed that it retained
identical affinity for androgen compared with full-length SHBG (dissociation constant 1.92 nM).
Consistent with this, both full-length SHBG and SHBG-LG4 significantly increased DHT-mediated
transcriptional activity of the androgen receptor compared with DHT delivered without carrier
protein. Collectively, these data provide the first evidence that SHBG is a target for proteolysis and
demonstrate that a stable fragment derived from proteolysis of steroid-bound SHBG retains bind-
ing function in vitro. (Endocrinology 153: 3179–3189, 2012)
Prostate cancer is the most common newly diagnosedcancer in the United States and is the third leading
cause of cancer-related death in men (1). Early stage pros-
tate cancer is dependent on sex steroids, and hence, the
disease is designated a “hormone dependent cancer” (2).
The developing prostate is also reliant on the androgens
testosterone and its reduced metabolite, 5-dihydrotes-
tosterone (DHT). Classical androgen signaling proceeds
through the androgen receptor (AR), which resides intra-
cellularly (3) and binds androgens that freely diffuse
through plasma membranes (4, 5). After steroid binding,
the androgen-AR complex translocates to the nucleus,
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where it activates transcription of androgen-responsive
genes (6). This in turn drives proliferation and differenti-
ation of both the prostate stroma and epithelium. The
androgen dependence of the prostate is highlighted by an-
drogen deprivation, which leads to induction of apoptosis
in vitro and in vivo (7, 8). Accordingly, treatments for
recurrent hormone sensitive prostate cancer focus on an-
drogen ablation.
Delivery of androgens (and other sex steroids) to hor-
mone-responsive tissues is primarily mediated by sex hor-
mone-binding globulin (SHBG), the principal specific car-
rier of sex steroids in blood (9). SHBG is secreted from the
liver as a 373-amino acid glycoprotein that circulates as a
homodimer. Each SHBG subunit consists of two laminin
G-like (LG) domains termed the LG4 (N-terminal) and
LG5 (C-terminal) domains. Individual steroid-binding
pockets are locatedwithin the LG4 domain of eachmono-
mer (10, 11), which bind testosterone and estradiol with
nanomolar affinities (9). In addition to steroidbinding, the
LG4 domain mediates dimerization (11, 12), divalent
metal ion binding (13), and interaction with the putative
SHBG cell-surface receptor (RSHBG) (14). However, the
biological function of the LG5 domain is yet to be
elucidated.
Several interactions between SHBG and extracellular
proteins have been identified which are suggested to aid
efficient steroid transport and delivery. SHBG binds to
matrix-associated proteins fibulin-1D and fibulin-2
within uterine stroma resulting in preferential sequestra-
tion of estradiol-bound SHBG from circulation (15). The
nonspecific endocytotic membrane receptor for the vita-
min A and D carrier protein (megalin) has also been dem-
onstrated to bind and internalize SHBG-steroid com-
plexes in mice (16). This is proposed to aid steroid entry
into target cells, although activation of a secondary sig-
naling response by this process remains to be confirmed in
a physiological context. Additionally, nontransport func-
tions have been postulated for SHBG. The high binding
affinity of androgens and estrogens to SHBG sequesters
these active steroids, thereby restricting steroid bioavail-
ability (5) andmodulating both stability and rate of clear-
ance of steroids from the bloodstream (17–19). Further,
glycosylation-variant SHBG shows cytoplasmic accumu-
lation and may act as a reservoir of androgen in mouse
proximal convoluted tubule cells (20). It has also been
proposed that SHBG participates in nongenomic steroid
signaling via RSHBG as distinct from classical androgen
and estrogen pathways (21, 22), although this remains a
matter of debate.
Although it is clear that proteolysis can modulate the
binding affinity of steroid carriers, such as corticosteroid
binding globulin (23, 24), a similar mechanism involving
SHBGhas not been reported. A previous yeast two-hybrid
screen examining interaction between prostatic proteins
and human SHBG identified the kallikrein-related pepti-
dase (KLK)4 as a potential interacting partner (25). KLK4
belongs to the 15-member tissue KLK family (26, 27) and
isover expressed inprostate cancer comparedwithnormal
prostatic tissue (28–31). Because expression of KLK4 and
a number of other KLKs are regulated by androgens (32),
interaction between SHBG and KLK proteases may influ-
ence biological functions of SHBG and the androgen sig-
naling axis within the prostate.
Here,we examine interactions between SHBGand four
closely relatedmembers of the KLK family (KLK3, KLK4,
KLK7, and KLK14), which show varying levels of andro-
gen responsiveness, to establish whether SHBG is a sub-
strate for these proteases. For KLKs found to cleave
SHBG, protease cut sites were identified by N-terminal
sequencing of proteolysis fragments, and the effect of oc-
cupying the steroid binding pocket on proteolysis was de-
termined by assays with DHT-bound SHBG. Functional
consequence(s) ofKLK-mediated SHBGcleavagewere de-
termined by characterizing steroid binding affinity of full-
length and cleaved SHBG in [3H]-DHTbinding assays and
exploring the ability of each species tomodulate transcrip-
tional activity of the AR, an indicator of androgen bio-
availability in cell culture. Collectively, these data suggest
a selective cleavage and processing of SHBG by KLKs.
Materials and Methods
Reagents
SHBG purified from human serum was obtained from
Fitzgerald Industries (Acton, MA). Recombinant KLK7 was
sourced from R&D Systems (Minneapolis, MN). Thermolysin
was obtained from Calbiochem (San Diego, CA), and active
prostate-specific antigen (PSA) from human seminal plasma,
DHT, BSA, and phosphoramidon were from Sigma-Aldrich
(Castle Hill, Australia). Antibodies for Western blot analysis
were rabbit antihuman SHBG polyclonal antisera (33), mouse
anti-V5 primary antibody (Invitrogen, MountWaverly, Austra-
lia), Alexa Fluor 680-conjugated goat antirabbit secondary an-
tibody (Invitrogen), and Alexa Fluor 488-conjugated goat anti-
mouse secondary antibody (Invitrogen). All reagents for cell
culture and reverse transcriptase PCR were from Life Technol-
ogies (Carlsbad, CA) unless otherwise stated.
Recombinant protein expression
Recombinant pro-KLK4 and pro-KLK14 were produced in
Sf9 insect cells as described previously (34, 35). Recombinant
human SHBG-glutathione S-transferase (GST) fusion proteins
(full length or SHBG-LG4 comprising residues 1–205)were pro-
duced in Escherichia coli as described previously (36). For an-
drogen signaling assays, recombinant SHBG-LG4 was liberated
from GST by overnight cleavage with thrombin and purified
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using a two-step chromatography method according to Grishk-
ovskaya et al. (37).
GST pull-down interaction analyses
Full-length SHBG-GST (20g) and an equimolar quantity of
GSTwere each immobilized on glutathione Sepharose resin (100
l) for 1 h at 4C (protein loading forGSHbeadswas normalized
using Bradford assay). Steroid-bound SHBG-GST was prepared
by preincubation with DHT (100 nM). SHBG-GST interaction
analyses were performed according to Ng et al. (15). Briefly,
pro-KLK4 or pro-KLK14 (1.25 g) was incubated with SHBG-
GST or GST resin overnight at 4 C in binding buffer (100 l)
containing 20 mM Tris-HCl (pH 8.0), 2.5 mM CaCl2, 0.02%
Nonidet P-40, and 0.2 mg/ml BSA. Sepharose-bound complexes
were sedimented by centrifugation, and resin was washed three
timeswith binding buffer (without BSA). Interacting proteinwas
extracted by boiling in reducing SDS-PAGE loading buffer, re-
solved by SDS-PAGE, transferred to a nitrocellulose membrane,
and detected byWestern blot analysis against the V5 epitope on
both pro-KLK4 and pro-KLK14.
Activation of pro-KLK
Pro-KLK4, pro-KLK7, and pro-KLK14 were activated with
thermolysin, which was inhibited by 40 M phosphoramidon
immediately after activation. Active KLK4 for [3H]-DHT bind-
ing assays was purified from thermolysin by anion exchange
chromatography using a Pharmacia ResourceQ anion exchange
column (Amersham Biosciences, Piscataway, NJ).
Proteolysis of SHBG by KLK3, KLK4, KLK7, and
KLK14
Active KLKs with trypsin-like specificity (KLK4, 7 nM;
KLK14, 10 nM) or chymotrypsin-like specificity (KLK3, 130 nM;
KLK7, 120 nM)was incubatedwith SHBG (350 nM) for 2 h at 37
C in buffer (10 l) containing 0.1 M Tris-HCl (pH 7.5), 0.1 M
NaCl, 1.5 mM EDTA, and 0.02% Tween 20. Reactions were
quenched by boiling in reducing SDS-PAGE loading buffer, after
which fragmentswere separated by SDS-PAGEand examinedby
Western blot analysis for SHBG. To examine kinetics of SHBG
proteolysis by KLK4 and KLK14, six concentrations of human
SHBG (100–2000 nM) were incubated with a constant concen-
tration of either KLK4 (7 nM) or KLK14 (10 nM) at 37 C for 2 h
(KLK14) or 4 h (KLK4). Samples were taken at intervals (15min
for KLK14, 30 min for KLK4), diluted in reducing loading buf-
fer, and heated at 95 C to quench protease activity. Triplicate
blots for each SHBG concentration were subjected to densito-
metric analysis using aLI-COROdyssey infrared imaging system
for undigested SHBG (48 kDa). Data were compiled using
GraphPad Prism 5.01 (GraphPad, San Diego, CA) and KM (Mi-
chaelis constant), kcat (catalytic rate constant), and kcat/KM val-
ues determined by nonlinear regression.
N-terminal sequencing of SHBG proteolysis
fragments
HumanSHBG(1g)was incubatedwithKLK4orKLK14 for
45 or 120 min at 37 C as described above. Samples from each
KLK digestion were pooled, lyophilized, and resuspended in re-
ducing SDS-PAGE loading buffer. Proteolysis fragments were
resolved by SDS-PAGE, transferred to a polyvinyl difluoride
membrane in N-cyclohexyl-3-aminopropanesulfonic acid buf-
fer, and stained with Coomassie R-250. After membranes had
been destained, proteolysis fragmentswere excised and analyzed
by Edman degradation N-terminal sequencing carried out at the
Australian Proteomic Analysis Facility (Sydney, Australia). To
assess whether identified cleavage sites were high-affinity sub-
strates for KLK4 or KLK14, putative P4-P1 residues (FNLR and
TSLR) were synthesized as peptide-paranitroanilides (pNA) ac-
cording to previously publishedmethods (35, 38) and incubated
with eachprotease according to Swedberg et al. (35),withkinetic
parameters (KM, kcat, and kcat/KM) determined by nonlinear re-
gression as described above.
Proteolysis of SHBG-DHT by KLK4 and KLK14
Human SHBG (200 nM)was incubatedwithKLK4orKLK14
for 2 h at 37 C (as above) in presence or absence of DHT (1 M)
or an equivalent volume of ethanol (steroid vehicle control). Pro-
teolysis fragments were examined by Western blot analysis for
SHBG.To confirm that effects proceeded through SHBG-steroid
interaction, control incubations were carried out with mouse
recombinant amelogenin (M179) produced in E. coli (39). Pu-
rified amelogenin (4 M)  DHT (1 M) or ethanol was incu-
bated with KLK4 and KLK14 for 1 h at 37 C. Samples were
separated by SDS-PAGE, stained with Coomassie R-250, and
visualized using a LI-COR Odyssey infrared imaging system.
[3H]-DHT binding assays and Scatchard analysis
HumanSHBGwas cleavedby incubationwithpurifiedKLK4
as described above except that reactions proceeded for 16 h to
maximize production of cleaved SHBG. Samples were examined
by anti-SHBG Western blot analysis after separation by native
and reducing SDS-PAGE to verify proteolysis of SHBG and gen-
eration of distinct fragments. Steroid-binding capacity of full-
length human SHBG, KLK4-cleaved human SHBG, and recom-
binant SHBG-LG4 was examined by ligand-saturation analysis
(40). SHBG species were incubated with [3H]-DHT (133.4 Ci/
mmol; GE Healthcare Life Sciences, Baie d’Urfe, Quebec, Can-
ada) followed by separation of bound and free steroid with dex-
tran-coated charcoal. Equilibrium dissociation constants (Kd)
were determined by Scatchard analysis (41) on measured levels
of SHBG-bound and free [3H]-DHT.
Androgen signaling assays
LNCaP cells were grown at 37 C in a 5%CO2 atmosphere in
RPMI1640medium supplementedwith 10%fetal bovine serum
(Thermo Fisher Scientific, Inc., Waltham, MA), penicillin (100
U/ml), and streptomycin (100 g/ml). LNCaP cells were seeded
into six-well tissue culture plates 1 d before treatment in 2 ml
phenol red-free RPMI 1640 medium containing 2% dextran
charcoal-treated fetal bovine serum. Cells were treated with
DHT(5nM) in the absence or presence of SHBG(5nM)or SHBG-
LG4 (5 nM) for 24 h; 6 nM SHBG-LG4 was used in the alcohol
dehydrogenase 7 (ADH7) analysis. mRNA was isolated using
TRIzol reagent (Life Technologies) according to the manufac-
turer’s instructions, followed by RT performed at 42 C for 50
min using 3 g of total RNA and 200 U of Superscript II. Quan-
titative (q)RT-PCR for PSA, ADH7, and 18S mRNA (internal
control) was carried out in 25l containing 12.5l of 2 SYBR
Green PCR master mix, 1 l of each forward (PSA, 5-CAAC-
CCTGGACCTCACACCTA; ADH7, 5-AGTTGCCCCACC
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AAAGACTAA; and 18S, 5-CGCCGCTAGAGGTGAAATT
CT) and reverse primer (PSA, 5-GGAAATGACCAGGCCAA-
GAC; ADH7, 5-AACTTGGACACCATTGTTCCTT; and 18S,
5-CGAACCTCCGACTTTCGTTCT), 2.5 l of RT product
(diluted 1:5) and 8 l of distilled H2O. Amplification was per-
formed using an ABI Prism 7000 Sequence 10 detection system
(Life Technologies) equipped with a 96-well optical reaction
plate. Negative controls, containing H2O instead of sample
cDNA, were included in each plate. All experiments were run in
triplicate, and mRNA values were calculated based on cycle
threshold and monitored for an amplification curve.
Androgen bioavailability assays
LNCaP monolayers established in 24-well plates were de-
prived of androgens by culture in serum-free media for 72 h.
Before treatment, SHBG (final concentration 35 nM) was incu-
batedwithDHT (3 nM) for 60min at 4 C as described in Ref. 42.
Cells were treated with fresh serum-free media containing either
DHT (3 nM), steroid-bound SHBG (35 nM), untreated SHBG (35
nM), or steroid vehicle control. Samples of media were taken at
0, 8, 16, and 24 h to monitor free androgen by DHT ELISA
(AlphaDiagnostic International, SanAntonio, TX) according to
the manufacturer’s instructions.
Results
Pro-KLK4 and pro-KLK14 interact with SHBG
GST pull-down assays were used to assess interaction
between SHBG and pro-KLKs. Zymogen KLKs were pro-
duced recombinantly with inclusion of a V5 epitope tag
allowing postinteraction analysis by Western blotting vi-
sualized with V5-specific antibody conjugates. Neither
pro-KLK4 nor pro-KLK14 interacted with immobilized
GST, whereas both zymogens interacted with the SHBG-
GST fusion protein as shown in Fig. 1. These data indicate
that both pro-KLK4 and pro-KLK14 bind to SHBG. To
examine effects of androgen on SHBG binding, incuba-
tions were performed in the presence of DHT. Interest-
ingly, pro-KLK4, but not pro-KLK14, binding to SHBG
was markedly accentuated by the presence of androgen
(Fig. 1). Nonspecific interaction with GST-only appeared
not to be affected by DHT treatment (data not shown).
Differential effects of DHT on pro-KLK/SHBG binding
suggest that despite a high degree of sequence and struc-
tural similarity, pro-KLK4 and pro-KLK14 interactions
with SHBG potentially involve enzyme-specific SHBG
contacts.
SHBG is a substrate for KLK4 and KLK14 but not
KLK3 or KLK7
Having shown that zymogenKLK4andKLK14bind to
SHBG,wewere interested inwhether active forms of these
trypsin-like serine proteases cleave SHBG. Additionally,
we assessed the SHBG cleaving ability of two other mem-
bers of the KLK family, KLK3 and KLK7, which have
chymotrypsin-like substrate specificity. Low concentra-
tions of active KLK4 (7 nM) and KLK14 (10 nM) and
greater than 10-fold higher concentrations of KLK3 (130
nM) and KLK7 (120 nM) were incubated with human
SHBG and analyzed byWestern blot analysis using a rab-
bit anti-SHBG polyclonal antibody. This showed that al-
though KLK4 and KLK14 cleave SHBG (Fig. 2), this pro-
tein is not efficiently cleaved by KLK3 and KLK7, which
show only low level proteolysis of SHBG after a 2-h in-
cubation (data not shown). Given that all recombinant
KLKs were proteolytically activated with thermolysin,
thermolysin/SHBG control digests were performed, and
no cleavage was observed (see Supplemental Fig. 1, pub-
lishedonTheEndocrineSociety’s JournalsOnlineweb site
at http://endo.endojournals.org). In addition, distinct pro-
teolysis fragments generated by KLK4 and KLK14 indi-
cated that each protease has individual SHBG cleavage
preferences. KLK4 proteolysis generated a predominant
fragmentof 25kDa inaddition to a secondbandof slightly
higher molecular weight (Fig. 2A), whereas KLK14 pro-
duced fragments of 30, 25, and 20 kDa (Fig. 2B).
Kinetics of SHBG proteolysis by KLK4 and KLK14
were examined by Michaelis-Menten plots of data from
anti-SHBGWestern blot analyses from three independent
experiments.Densitometry analysiswasperformedonun-
cleaved SHBG (48 kDa) with the reduction in signal in-
tensity over time used as a measure of proteolytic activity.
Plots of degradation against time followed pseudo first
FIG. 1. GST interaction analyses between SHBG and pro-KLKs. Pro-
KLK4 (A) or pro-KLK14 (B) interacting with GST and SHBG-GST fusion
protein. Interacting protein was analyzed by Western blot analysis
against the V5 epitope on recombinant pro-KLK4 and pro-KLK14 after
overnight binding to immobilized GST or SHBG-GST. Additionally,
interaction with SHBG-GST preloaded with DHT was examined to
determine the effect of steroid binding on the SHBG-KLK interaction.
GST alone controls confirmed that the binding interaction was specific
for SHBG. Western blots are representative of three independent
experiments.
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order kinetics providing kinetic constants for proteolysis
of SHBG (Table 1), which yielded kcat/KM values of 1.6
104 M1 sec1 and 3.8  104 M1 sec1 for KLK4 and
KLK14, respectively.
KLK4 and KLK14 cleave SHBG between the LG4
and LG5 domains with unique specificities
Fragments liberated by KLK4 and KLK14 cleavage of
SHBG (Fig. 3A) were analyzed by Edman degradation
N-terminal sequencing of material electroblotted onto
PVDF immobilon to determine cut sites for each protease.
Sequence data (Table 2) identified two predominant cut
sites: one generated immediately after Arg186 (fragment
1) and one commencing after Arg209 (fragment 2). Frag-
ment 3 corresponded to the N terminus of full-length
SHBG (undefined C terminus) as determined by Edman
degradation of material from KLK14 digests. The comi-
grating band from KLK4-digested material did not pro-
vide N-terminal sequence data. However, it is logical to
assume that this KLK4-derived fragment also constitutes
the N-terminal domain on the basis that it binds steroid
(see below), and this activity is N-terminal domain depen-
dent (11, 36). Both cut sites were located on the region
between the two LG domains of SHBG, illustrated in Fig.
3B. To confirm that identified cut sites were high-affinity
substrates for KLK4 or KLK14, the four nonprime resi-
dues (P4–P1) of each cut site were synthesized as peptide-
pNA substrates. Kinetic constants were determined for
cleavage of these substrates corresponding to cut site pref-
erence of each protease (KLK4/FNLR-pNA and KLK14/
TSLR-pNA). Calculated kcat/KM values (Table 1) verified
cleavage with high efficiency.
Generating sufficient amounts of each KLK14 prote-
olysis fragment for sequencing proved difficult, because
the products after the initial cleavage events were rapidly
digested further. Consistent with this, abundance of
KLK14proteolysis fragments did not noticeably change in
previous time-course digestions despite continuing prote-
olysis of full-length SHBG(Fig. 2B). In contrast, fragments
produced by KLK4 seemed to accumulate over the dura-
tion of the assay (Fig. 2A). This suggested that not only did
KLK4 and KLK14 cleave SHBG at distinct sites, but ad-
ditionally, the fate of proteolysis fragments generated by
eachenzymewasdifferent.Toexamine this further, longer
duration SHBG digestions were carried out with KLK4
and KLK14. Fragments were detected by silver stain to
overcomeanybias in epitope recognitionwhenvisualizing
proteolysis products by Western blot analysis. For KLK4
digestions, two bands of similar size were apparent and
persisted even after 16 h of digestion (Fig. 3C), suggesting
that cleavage was limited to a single cut site and products
were resistant to further degradation. This doublet be-
comes more apparent when higher protein loadings are
visualized byWestern blot analysis (see Supplemental Fig.
2). In contrast, prolonged incubations with KLK14 re-
sulted in loss of all detectable fragments, indicating that
proteolysis of SHBG by this enzyme was a degradative
processing event.
DHT alters KLK4 and KLK14 proteolysis of SHBG
Given SHBG’s high affinity for sex steroids, we con-
sidered the possibility that DHT binding might influence
FIG. 2. SHBG is cleaved by KLK4 and KLK14. Purified human SHBG
digested with active KLK4 (A) or KLK14 (B). Varying concentrations of
SHBG were digested with a constant concentration of protease to
calculate semiquantitative kinetic constants (1000 nM SHBG digestion
is shown). Protease activity was quenched by heating to 95 C in
reducing SDS-PAGE loading buffer, after which SHBG digestion
products were separated by SDS-PAGE and analyzed by Western
blotting. Blots were visualized using the LI-COR Odyssey infrared
imaging system and are representative of three independent
experiments.
TABLE 1. Kinetic constants for SHBG and peptide-pNA KLK digestions
Protease/substrate KM kcat kcat/KM
KLK4/SHBG 1.20.7M 0.020.01sec1 1.60.5104M1sec1
KLK4/FNLR-pNA 111.66.6M 5.070.09sec1 4.60.7104M1sec1
KLK14/SHBG 2.10.6M 0.080.01sec1 3.80.5104M1sec1
KLK14/TSLR-pNA 181.69.8M 18.800.42sec1 10.41.1104M1sec1
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KLK-mediated proteolysis. Accordingly, SHBG proteol-
ysis assayswere carried outwith andwithout exogenously
added androgen. DHT-bound SHBG showed noticeably
reduced rates of proteolysis byKLK4 (Fig. 4B) andKLK14
(Fig. 4C), suggesting that steroid binding exerts a stabi-
lizing influence on SHBG. Further, ligand-bound SHBG
showed a shift in cut site preference when digested by
KLK14 being cleaved predominantly at Arg209. In con-
trol digestions with amelogenin, a substrate common to
KLK4 and KLK14, DHT did not influence proteolysis by
either enzyme (Fig. 4, E and F), confirming that altered
proteolysis of SHBG was driven by steroid binding to
SHBG rather than a KLK-DHT interaction.
SHBG-LG4 domain proteolysis
fragment retains identical
androgen binding affinity
Previous studies have indicated that
the LG4 (N-terminal) domain is re-
sponsible for the majority of biological
functions of SHBG, including steroid
binding (11). Because proteolysis of
DHT-bound SHBG appeared to liber-
ate an intact LG4domain from theLG5
domain, we assessed its androgen bind-
ing affinity to determinewhether it was
functional. Initially, digestion frag-
ments were analyzed under native con-
ditions to confirm that proteolysis re-
sulted in separation of LG4 and LG5
domains todiscount thepresenceof any
substantial noncovalent interdomain
interactions. Western blot analysis ver-
ified production of distinct fragments
aswell as a lackofdetectable full-length
SHBG (Fig. 5A). Steroid binding capac-
ities of full-length and cleaved human
SHBG were measured by saturation
binding assays, from which binding af-
finities were determined by Scatchard
plot analysis. Remarkably, despite pro-
teolytic separation from the LG5 do-
main, the [3H]-DHT binding curve for
cleaved SHBG overlayed precisely with
full-length SHBG. Consistent with this, calculated Kd
from Scatchard analysis (Fig. 5C) were identical (Kd
SHBG-DHT 1.92 nM vs. Kd SHBG/KLK4-DHT 1.92
nM). Collectively, these findings indicate that the ability of
the SHBG cleaved by KLK4 to interact with steroid is
undiminished.
Native SHBG and SHBG-LG4 both enhance DHT-
mediated stimulation of the AR
SHBG’s high affinity for DHT and testosterone will
influence local androgen bioavailability and, thus, access
of signaling molecules to intracellular receptors (43). Ob-
servation of equivalent binding affinities for native SHBG
FIG. 3. N-terminal sequencing of SHBG proteolysis fragments reveals distinct cut sites for
KLK4 and KLK14. A, SHBG proteolysis fragments generated by KLK4 and KLK14 visualized by
Western blot analysis from Fig. 2 (120 min, KLK4; 60 min, KLK14). Fragments excised for
Edman degradation N-terminal sequencing are indicated by an asterisk, and sequence data
returned for fragments 1–3 are shown in Table 2. B, Schematic representation of human
SHBG showing the N-terminal (LG4) and C-terminal (LG5) LG domains with fragments
generated by proteolysis shown below. Sequence analysis indicated that the cleavage sites
occurred between the two LG domains. C, Comparison of the specificity of SHBG cleavage by
KLK4 and KLK14. SHBG (50 ng) was digested with 7 nM KLK4 or 10 nM KLK14 for 2 or 16 h
at 37 C. Fragments were resolved on 4–12% gradient gels and detected by silver stain.
Incubation with KLK4 resulted in a single cleavage event with generated fragments resistant
to further digestion, whereas no detectable fragments were visible after 2 h of digestion with
KLK14. KLK4 and KLK14 control lanes contain proteases only.
TABLE 2. Amino acid sequence from Edman degradation N-terminal sequencing of fragments generated by KLK4
and KLK14 proteolysis of SHBG
Proteolytic incubation Fragment Sequence
Cleavage site residues
P4 P3 P2 P1/P1 P2 P3 P4
KLK14-SHBG 1 187SCDVES 183T S L R/S C D V
KLK4-SHBG 2 210DIPQPH 206F N L R/D I P Q
KLK14-SHBG 3 1LRPVLP N-terminus of mature SHBG
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and the SHBG-LG4 domain prompted us to assess their
impact on androgen-driven transcription. Transcriptional
activity of the ARwasmeasured by expression of PSA and
ADH7 in qRT-PCR assays after DHT stimulation. Ste-
roid-binding capacities of SHBG and recombinantly ex-
pressed SHBG-LG4 were first determined in cell culture
media to confirm equivalence with previous experiments.
Scatchard analysis (Fig. 6, A and B) revealed similar bind-
ingaffinity for SHBG-LG4andSHBG(Kd1.23and0.97
nM, respectively). These values are lower than those of the
previous assays reflecting the change in assay conditions
from simple buffer to cell culture medium. The small dif-
ference in affinity of native SHBG and SHBG-LG4 was
consistent in three separate experiments and reflects the
inherent difference in affinity between full-length native
SHBG and the recombinant SHBG-LG4 domain ex-
pressed in E. coli, as observed previously (36).
The ability of each SHBG species to influence DHT-
stimulatedandrogen signalingwas examined in culturesof
the androgen-responsive cell line, LNCaP (Fig. 6, C and
D). Addition of 5 nM DHT elevated PSA and ADH7 ex-
pression compared with vehicle-treated cells (P  0.05).
However, this effect was significantly increased by deliv-
ering steroid in complex with SHBG compared with ste-
roid alone (P  0.05), irrespective of whether DHT was
bound to native SHBG or recombinant SHBG-LG4. This
suggested that binding DHT to SHBG enabled more ste-
roid to stimulate the AR, potentially by provision of a
reservoir of steroid that could be gradually released over
time while simultaneously protecting it from breakdown
in the extracellular environment. Further, this demon-
strated that the SHBG-LG4 domain was sufficient to
achieve this DHT-dependent effect. To ascertain whether
steroid-free SHBG alone could stimulate PSA production,
we treated LNCaP cells with SHBG protein but could not
detect increased PSA expression (see Supplemental Fig. 3).
To confirm that binding of steroid to SHBG resulted in
prolonged androgen presence in vitro, the residual con-
centration of bioavailable DHT was quantified by DHT
ELISA (Fig. 6E) in LNCaP culture media over 24 h. In
treatments ofDHTwithout SHBG,bioavailableDHTwas
abundant at 0 h but was rapidly depleted within 8 h. In
FIG. 4. DHT modulates KLK proteolysis of SHBG. A–C, Western blot
analysis for buffer only, ethanol (EtOH) vehicle, or DHT-treated SHBG,
which was not digested (A), digested with KLK4 (B), or digested with
KLK14 (C). D–F, Coomassie R-250-stained SDS-PAGE analysis for
buffer only, ethanol vehicle, or DHT-treated recombinant mouse
amelogenin, which was not digested (D), digested with KLK4 (E), or
digested with KLK14 (F). Gels were visualized using the LI-COR
Odyssey infrared imaging system. All figures are representative of three
independent experiments.
FIG. 5. High steroid-binding affinity of SHBG is maintained after KLK4
proteolysis. A, Western blot analysis of intact and KLK4-cleaved SHBG
(16 h at 37 C) after reducing (left) and native (right) PAGE confirming
proteolysis of SHBG produces separate fragments. B, Saturation curve
for binding of various concentrations of [3H] DHT to a constant
concentration of full-length SHBG (closed circles) or KLK4-cleaved
SHBG (open circles), the vertical axis shows [3H]-DHT binding as
indicated by counts pre minute (cpm). C, Scatchard analysis
transformed from saturation curve data indicating that the steroid-
binding affinities of native SHBG (Kd  1.92 nM) and KLK4-cleaved
SHBG (Kd  1.92 nM) are identical. A representative plot is shown from
three independent experiments.
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contrast, steroid delivered in complex with SHBG, free
DHTwas lower at 0h, because aproportionof steroidwas
bound to the carrier protein. However, it was more effi-
ciently retainedwith detectable levels present at every time
interval, and only a gradual decline was observed by 24 h.
No steroid was detected in media containing untreated
SHBG, confirming a lack of contaminating androgen.
This reinforced that binding to SHBG
greatly increased retention of DHT in
the in vitro extracellular milieu.
Discussion
Prostate physiology is dominated by
androgen signaling, which dictates
prostatic development and is the prime
point of therapeutic intervention in
prostate cancer (44).Delivery of andro-
gens to target tissues, enhancement of
their stability, and regulation of their
bioavailability are primary functions of
the steroid-binding protein, SHBG
(45). Therefore, SHBG determines the
ability of steroids to effect androgen-
responsive gene expression with poten-
tial significance to tumorigenesis
within the prostate. To date, knowl-
edge of SHBG binding proteins is fairly
limited. Further, interaction validation
and characterization are confined to a
sparse subset of targets, such as uterine
stroma matrix-associated proteins
fibulin-1D and fibulin-2 (15) and the
nonspecific cell-surface receptor mega-
lin (16). Moreover, proteolytic modu-
lation of SHBG steroid carriage and de-
livery has not been investigated, despite
identification of this phenomenon in
other steroid binding proteins, such as
corticosteroid binding globulin (23,
24). Hence, this study is the first to es-
tablish that SHBG is a target for
proteolysis.
That a protease is able to cleave a
given protein is not in itself a remark-
able finding. The potential significance
lies in the efficiency of proteolysis and
the resulting biological effects. Kinetic
analysis ofpNAsubstrate hydrolysis by
both KLK4 and KLK14 indicated that
sequences identified by N-terminal se-
quencing were cleaved with high effi-
ciency. Recent studies onKLK4 found a second-order rate
constant of 2.31  104 M1 sec1 for its most preferred
tetrapeptide-pNA substrate (35), which is very similar to
that measured for FNLR-pNA in this study (4.61  104
M
1 sec1). Efficiency for cleavage of TSLR-pNA by
KLK14 (1.04  105 M1 sec1) is more distant from its
FIG. 6. Native SHBG and recombinant SHBG-LG4 both increase androgen action in LNCaP
cells by sustaining androgen bioavailability in cell culture. A, Saturation binding curve for
intact SHBG (closed circles) and SHBG-LG4 domain (open circles) in culture medium, using
[3H]-DHT as a labeled ligand, the vertical axis shows [3H]-DHT binding as indicated by counts
per minute (cpm). B, Scatchard plot showing the steroid-binding affinities of SHBG (Kd  0.97
nM) and SHBG-LG4 (Kd  1.23 nM) in culture medium are similar. Analyses were performed
on samples taken from triplicate experiments, which all showed the same results, and a
representative plot is shown. C, Human ADH7 mRNA was measured by qRT-PCR in LNCaP
cells grown in phenol red-free RPMI 1640 medium supplemented with 2% charcoal-treated
fetal bovine serum, after treatments with DHT (3 nM) in the absence or presence of SHBG (3
nM) or SHBG-LG4 (6 nM) for 24 h. 18S mRNA was also measured as an internal control.
Values represent mean  SD of three separate experiments. Significant differences are **, P 
0.01; *, P  0.05 comparing DHT, SHBG plus DHT, and SHBG-LG4 plus DHT-treated cells to
vehicle-treated cells. #, P  0.05 for SHBG plus DHT and SHBG-LG4 plus DHT vs. DHT-treated
cells. D, Human PSA mRNA was measured by qRT-PCR in LNCaP cells as described for the
previous panel except concentrations used were SHBG (5 nM), SHBG-LG4 (5 nM), and DHT (5
nM). E, DHT ELISA for bioavailable androgen in cell culture media over 24 h. Serum-starved
LNCaP cells were treated with serum-free media containing 3 nM DHT (open circles), 35 nM
untreated SHBG (triangles), or 35 nM SHBG preloaded with 3 nM DHT (closed circles). Data
were expressed as a fold-change over DHT measured at 0 h in 3 nM free DHT treatments as
mean  SEM of three independent experiments. *, P  0.05 for SHBG plus DHT vs. DHT only.
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most preferred peptide substrate identified to date (3.81
106 M1 sec1) (46). Proteolysis of SHBG yielded second-
order rate constants of 1.67 104 M1 sec1 with KLK4
and 3.81 104 M1 sec1 with KLK14. These values are
comparable with those seen for a variety of proteases for
turnover of in vivo substrates, such as processing of von
Willebrand factor by ADAMTS-13 (3.4 104 M1 sec1)
(47),Gag-Pol polyprotein byHIVprotease (2.9104M1
sec1) (48), or hydrolysis of mucin by StcE (2.61  104
M
1 sec1) (49). Comparison of catalytic efficiency of
KLK4 and KLK14 to these enzymes suggests that SHBG
may be an in vivo substrate.
Also striking is the nature of the substrate and effecting
protease(s). SHBG is the principal specific carrier and dis-
tributor of androgens and estrogens, whereas expression
patterns for KLK proteases are renowned for being highly
influenced by sex steroids (32). This suggested KLK pro-
teolysis of SHBGmaybe analogous to the previously iden-
tified proteolytic regulation of corticosteroid binding pro-
tein (23, 24). Ligand-free SHBG was cleaved by KLK4
neatly into its two separate domains, which were highly
resistant to further proteolysis even after prolonged incu-
bation. This is reminiscent of proteolytic processing of the
structurally related laminin 5 by bonemorphogenetic pro-
tein 1 (50),where the lamininGdomain (amotif shared by
SHBG) is precisely cleaved to produce proteolytically re-
sistant fragments.KLK14activity on the other hand seems
to be far more promiscuous. Although we were able to
gatherN-terminal sequencingdataon the larger fragments
produced by KLK14, these products were very rapidly
degraded to residual peptides, abrogating SHBG’s biolog-
ical activity.
Proteolysis of unoccupied SHBG contrasted with an-
drogen-bound SHBG,whichwas cleaved by bothKLKs at
noticeably reduced rates and only at sites within the LG5
domain, thus leaving the steroid-binding LG4 domain in-
tact. Previous structural analyses of SHBG in complex
with DHT (10) and estradiol (51) have identified several
LG4 domain conformational shifts that are dependent on
bound steroid, including across a region homologous to a
macromolecular interaction domain in structurally re-
lated proteins (52). Such an effect may explain both the
distinct change in KLK14 cleavage site preference ob-
served upon DHT binding from predominantly Arg186
(within the LG4 domain) to exclusively Arg209 (LG5 do-
main) and the markedly higher binding of pro-KLK4 to
SHBG-GST in the presence of androgen. Ligand-depen-
dent changes in conformation may be common in mech-
anisms regulating SHBG function. Indeed, steroid-specific
effects are evident in several of SHBG’s previously char-
acterized binding interactions. The interaction between
SHBG and members of the fibulin family of extracellular
matrix-associated proteins occurs more efficiently in the
presence of estradiol than in the presence of DHT (15),
whereas SHBG cannot bind to its putative cell-surface re-
ceptor when bound with steroid (21).
However, unlike corticosteroid binding globulin,
where proteolysis results in release of the bound steroid
(23, 24), subsequent characterization of SHBG-LG4 re-
vealed identical steroid binding affinity compared with
native SHBG (Fig. 5). Because cleavage of SHBG at
Arg209 would leave the LG4 domain intact, this is in ac-
cordance with existing studies, which have suggested that
the LG4 domain of SHBG is solely responsible for steroid
binding (10, 11). Additionally, the LG4 domain alone is
capable of dimerization (11, 12) and interaction with
RSHBG (14), indicating that the SHBG proteolysis frag-
ment identified in this study is functional. Consistent with
indistinguishable steroid-binding properties, removal of
the C-terminal LG5 domain did not alter SHBG’s influ-
ence on the androgen signaling axis in cell culture. An-
drogen-responsive PSA and ADH7 expression was signif-
icantly increased by delivering DHT in complex with
either full-length SHBG or SHBG-LG4, indicating a grad-
ual release of DHTby SHBGor SHBG-LG4 as opposed to
rapid internalization and metabolism as described previ-
ously (42).
Lack of knowledge of the structure and function of the
LG5 domain hampers understanding the full significance
of SHBG proteolysis. Unaltered steroid binding and bio-
availability findings from this study indicate that SHBG
proteolysis by KLK4 is not aimed at changing the inter-
action between SHBG and its bound steroid. Rather, a
yeast two-hybrid screen using the SHBG-LG5 domain
identified several hitswithin a prostate cDNA library, sug-
gesting that the primary function of the LG5 domain may
be to mediate protein-protein interactions (53). The latter
study also identified KLK4 as an LG5 domain interactor,
confirmed here because KLK4 cleaves SHBG at Arg209.
Resolving the function of the LG5 domain will be pivotal
to understanding the potential significance of SHBG pro-
teolysis. In themeantime, thedistinct endocrine regulation
of the twoKLKs found to cleave SHBG offers a promising
lead. Although bothKLK4 (28) andKLK14 (54) aremod-
erately expressed in the prostate, their expression is not
equally influenced by androgens: only KLK4 is highly up-
regulated after testosterone stimulation (55), not KLK14
(32). However, KLK14 is highly expressed under the in-
fluence of estrogens, including estradiol (56), and more
abundantly expressed in the breast (54). Testosterone and
estradiol are the twoprinciple steroid ligandsof SHBG(9),
hence differential processing of SHBG by KLK4 and
KLK14might contribute to parallel mechanisms with sig-
nificance to the androgen and estrogen signaling axes in
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separate hormone sensitive tissues. Consistent with
KLK4’s association with prostate cancer, several reports
have foundKLK14 expression to be linkedwith prognosis
of breast cancer patients (56, 57).This provocative finding
warrants further investigation.
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